ID: ALA264070

Max Phase: Preclinical

Molecular Formula: C23H34N4O4

Molecular Weight: 430.55

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCn1c(=O)c2nc([C@]34CC[C@](CCCC(=O)O)(CC3)CC4)[nH]c2n(CCC)c1=O

Standard InChI:  InChI=1S/C23H34N4O4/c1-3-14-26-18-17(19(30)27(15-4-2)21(26)31)24-20(25-18)23-11-8-22(9-12-23,10-13-23)7-5-6-16(28)29/h3-15H2,1-2H3,(H,24,25)(H,28,29)/t22-,23-

Standard InChI Key:  BGGPFCJYYBWGTM-YHBQERECSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 430.55

Molecular Weight (Monoisotopic): 430.2580

AlogP: 3.55

#Rotatable Bonds: 9

Polar Surface Area: 109.98

Molecular Species: ACID

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 4.47

CX Basic pKa: 2.46

CX LogP: 3.88

CX LogD: 1.00

Aromatic Rings: 2

Heavy Atoms: 31

QED Weighted: 0.63

Np Likeness Score: -0.05

References

1. Kiesman WF, Zhao J, Conlon PR, Dowling JE, Petter RC, Lutterodt F, Jin X, Smits G, Fure M, Jayaraj A, Kim J, Sullivan G, Linden J..  (2006)  Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists.,  49  (24): [PMID:17125264] [10.1021/jm0605381]

Source

Source(1):

• Scientific Literature